Nothing new under the sun: Little new among psych meds in decades, Part II: The antipsychotics

“The data are in, and it is clear that . . .a[n] experiment has failed: despite decades of research and billions of dollars invested, not a single mechanistically novel drug has reached the psychiatric market in more than 30 years.”… Continue Reading


How the World of the Atypical Passed Me By–and How I Could Use Your Help

I blithely wrote a post for my blogging day job on the atypical antipsychotics, cleverly (or so I thought at the time, at least) entitling it “The Atypical History of Atypical Antipsychotics,” and I covered what I considered the big… Continue Reading


Atypical Attitudes: How The Atypicals Took the Fall in Dementia Patients–The Beginning of Trouble

It was indisputably bad news for the makers of the new, second-generation (or atypical) antipsychotics–a literal black mark on their name. It was April, 2005, and the FDA issued an advisory that would strike fear into the hearts of any elderly… Continue Reading


Play It Again, Sam: Trying–and Failing–To Reproduce Scientific Results

With the release of Zyprexa, a second-generation antipsychotic, Eli Lilly was certain it had hit pay dirt. The second-generation antipsychotics, known as the atypical antipsychotics, or atypicals, had an improved side effect profile over the older antipsychotics, and the original… Continue Reading


The Bipolar Road Less Traveled: Beyond Lithium, Part I

Once upon a time, if you were diagnosed with bipolar disorder, you were treated with lithium. And, once upon a time, it worked. According to the Report of the Surgeon General, “Success rates of 80 to 90 percent were once… Continue Reading